To date, over 450 publications describe the immunopotentiating properties of ISCOM adjuvants in terms of antibody responses, cellular responses, cytokine and chemokine production, and protection against infection.
The new generation of ISCOM technology has opened up new applications in immunological research by overcoming drawbacks once associated with problematic formulations. Isconova’s next-gen adjuvant is easily handled with any antigen.
Isconova’s platform technology is available for licensing for many veterinary vaccine development segments. Our tailored business collaboration models are designed to fit your specific requirements and circumstances.
We can help improve and/or develop your vaccine products. Many livestock segments are open for collaboration and licensing.
Isconova's recent development of its adjuvant technology platform opens up new opportunities to develop human vaccines with outstanding performance and safety. We invite interested partners to explore the possibilities through research collaboration projects.

The AbISCO® adjuvant consistently induces the highest proliferation index and high production levels of antibodies.
Two cornerstone patent applications covering Isconova’s most recent development of its adjuvant technology platform with improved safety and efficacy has been granted in Europe.
The new formulations increase the adjuvant performance safety window by an order of magnitude, a result that has been verified in several species. The increased performance and safety is not limited to [...]